Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

ROCKET AF Steering Committee & Investigators2019-07-262019-07-262016ROCKET AF Steering Committee & Investigators 2016, 'Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF', JAMA, vol. 5, no. 3, e002197. https://doi.org/10.1161/JAHA.115.002197)0098-7484ORCID: /0000-0003-2115-8184/work/63243412http://hdl.handle.net/2164/12646The ROCKET AF trial was sponsored by Johnson & Johnson Pharmaceutical Research & Development (Raritan, NJ) and Bayer HealthCare AG (Leverkusen, Germany).1228054engatrial fibrillationmortalityrivaroxabanstrokewarfarinR MedicineRCause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AFJournal article10.1161/JAHA.115.002197)53